In the current study, we tested a second clinically available MAO inhibitor, phenelzine, which inhibits both MAO-A and MAO-B isoforms, and is FDA-approved for the treatment of panic disorder, social anxiety disorder, and treatment-resistant depression. The gene discussed is MAOA; the disease is social phobia.